NC Life Sciences Organization

Join us for Building High-Performing Teams Through Inclusive Leadership with Amgen, mdgroup and The Diversity Movement on Wednesday, July 24, from 4 to 6 p.m. at the NC Biotech Center. Come ready to network with industry leaders and to hear a panel discussion exploring proven inclusive leadership development strategies. Learn more and register at https://lnkd.in/gSD3N-hj

Novo Nordisk today announced plans to invest $4.1 billion dollars to build a second fill and finishing manufacturing facility in Clayton and grow its ability to produce current and future injectable treatments for people with obesity and other serious chronic diseases. Marking one of the largest manufacturing investments in Novo Nordisk’s history, the expansion will add 1.4 million square feet of production space for aseptic manufacturing and finished production processes, doubling the combined square footage of all three of the company’s existing facilities in North Carolina. It will also add 1,000 new jobs, besides the nearly 2,500 Novo Nordisk employees already working in the region, a central hub for innovation and biotechnology in the United States. Using state-of-the-art technology, roof-top solar panels and innovative water strategies, the facility is designed in an efficient and environmentally sustainable way to deliver the highest-quality products to patients around the world. The goal is to obtain LEED Gold certification, recognised as a standard of excellence in constructing healthy, efficient, carbon and cost-saving green buildings. https://lnkd.in/g-SG4EHy

A big thank you to Sen. Thom Tillis and Sen. Ted Budd for taking the time today to talk with NCLifeSci members about the R&D tax credit, the #smallmoleculepenalty in the #InflationReductionAct and IP protection and for answering members' questions.

“Fortunately, federal lawmakers have recognized the negative impact the pill penalty could have on new drug development. The bipartisan EPIC Act would equalize the period of price-control exemptions for small-molecule drugs and biologics at 13 years. This fix would once again put life sciences research back on a path to following the science, not a distorted incentive structure. That’s the right way forward for North Carolina innovators.” – Laura Gunter, NCLifeSci President In a recent opinion for The Carolina Times, NCLifeSci President Laura Gunter applauds Representatives Davis (NC-1), Murphy (NC-3), and Guthrie (KY-2) for introducing the Ensuring Pathways to Innovate Cures (EPIC) Act. Congress must pass the #EPICAct and ensure continued investment into new and innovative drug development here in North Carolina. Learn more about how the EPIC Act will protect innovation and support North Carolina’s robust life sciences industry in Gunter’s new op-ed: bit.ly/3VuW4KR

We're bridging the gap between industry and academia here in NC! Congratulations to our NC Life Sciences Organization partners Merck and NC A&T on their partnership and ribbon cutting for the Merck Biotech learning center! So awesome to see CMO Chirfi Guindo and so many other instrumental leaders at the celebration this morning.

April 26 is #WorldIPDay! Strong intellectual property (#IP) rights protect the innovative research and development that fuels North Carolina’s leading life sciences industry. Read more from NCLifeSci President Laura Gunter to learn how stripping IP protections could weaken our life sciences ecosystem ➡️ https://bit.ly/49P0Ma2

The specialized treatments required by 21st century medicine can only be achieved through highly sophisticated pre-clinical pharmacological research. Today, such research is truly global, involving program-critical ingredients and suppliers from all corners of the world. In 2017, Biocair began transporting API shipments from China to the US for a small, independent US-based research company focusing on innovative drug treatments. Over the years, Biocair's logistical support facilitated the progression of their drug development program from initial research, through clinical trial to Food and Drug Administration (FDA) submission and approval. What kind of logistical support did this require? 🧪 Maintaining drug development program continuity through mergers and acquisitions 🧪 Developing scalable packaging procedures 🧪 Providing expertise in exporting shipments from China and importing these to the US 🧪 Ensuring the proper classification and declaration of dangerous goods Learn more about the role that Biocair played in the success of this global drug development program in our most recent case study 👇 https://hubs.li/Q02sv_X70 #API #FDA #pharmaceutical #drugdevelopment #preclinical #movingscienceforward

Calling all innovators, inventors, and entrepreneurs to join the SBA North Carolina District Office as we host the USPTO Eastern Region on Tuesday, April 23rd for a virtual presentation on USPTO resources! Register Today: https://lnkd.in/g7FPbz4d

In a new opinion in the Daily News, NCLifeSci President Laura Gunter and Director of @IncubateCoalition John Stanford highlight how the Ensuring Pathways to Innovate Cures (EPIC) Act would protect investments in new medication development. The legislation would address a provision within the Inflation Reduction Act that implemented differing price negotiation eligibility timelines between small and large molecule medicines, leading to fewer incentives to research, develop, and commercialize certain medications. Learn more about why the #EPICAct is a critical step to support North Carolina’s life sciences industry: https://bit.ly/3VWGbx5

We look forward to tomorrow's #SBIR #STTR information session in North Carolina! Attendees will receive a detailed overview of the funding and resources our program can provide to accelerate your #Biotech commercialization journey. https://lnkd.in/gVYkUx7J